{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:03:07Z","timestamp":1777129387482,"version":"3.51.4"},"reference-count":96,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAIAD"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Both Stevens-johnson syndrome (SJS) and Toxic-epidermal necrolysis (TEN) are generally\nmedication-induced pathological conditions that mostly affect the epidermis and mucus\nmembranes. Nearly 1 to 2 patients per 1,000,000 population are affected annually with SJS and\nTEN, and sometimes these maladies can cause serious life-threatening events. The reported death\nrates for SJS range from 1 to 5%, and 25 to 35% for TEN. The mortality risk may even be higher\namong elderly patients, especially in those who are affected by a significant amount of epidermal\ndetachment. More than 50% of TEN patients who survive the illness may experience long-term\nlower quality of life and lesser life expectancy. The clinical and histopathological conditions of\nSJS and TEN are characterized by mucocutaneous discomfort, haemorrhagic erosions, erythema,\nand occasionally severe epidermal separation that can turn into ulcerative patches and dermal necrosis.\nThe relative difference between SJS and TEN is the degree of ulcerative skin detachment,\nmaking them two extremes of a spectrum of severe cutaneous adverse drug-induced reactions\n(cADRs). In the majority of cases, serious drug-related hypercreativities are considered the main\ncause of SJS &amp; TEN; however, herpes simplex virus and Mycoplasma pneumoniae infections may\nalso produce similar type clinical conditions. The aetiology of a lesser number of cases and their\nunderlying causative factors remain unknown. Among the drugs with a \u2018greater likelihood\u2019 of\ncausing TEN &amp; SJS are carbamazepine (CBZ), trimethoprim-sulfamethoxazole, phenytoin, aminopenicillins,\nallopurinol, cephalosporins, sulphonamides, antibiotics, quinolones, phenobarbital,\nand NSAIDs of the oxicam variety. There is also a strong genetic link between the occurrence of\nSJS and IEN in the Han Chinese population. Such genetic association is based on the human leukocyte\nantigen (HLA-B*1502) and the co-administration of carbamazepine. The diagnosis of SJS\nis made mostly on the gross observations of clinical symptoms, and confirmed by the histopathological\nexamination of dermal biopsies of the patients. The differential diagnoses consist of the\nexclusion of Pemphigus vulgaris, bullous pemphigoid, linear IgA dermatosis, paraneoplastic pemphigus,\ndisseminated fixed bullous drug eruption, acute generalized exanthematous pustulosis\n(AGEP), and staphylococcal scalded skin syndrome (SSSS). The management of SJS &amp; TEN is\nrather difficult and complicated, and there is sometimes a high risk of mortality in seriously inflicted\npatients. Urgent medical attention is needed for early diagnosis, estimation of the\nSCORTEN prognosis, identification and discontinuation of the causative agent as well as highdose\ninjectable Ig therapeutic interventions along with specialized supportive care. Historical aspects,\naetiology, mechanisms, and incidences of SJS and TEN are discussed. An update on the\ngenetic occurrence of these medication-related hypersensitive ailments as well as different therapy\noptions and management of patients is also provided.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2772270817666230821102441","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:37:17Z","timestamp":1692679037000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview\nof Diagnosis, Therapy Options and Prognosis of Patients"],"prefix":"10.2174","volume":"17","author":[{"given":"Vivek Kumar","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Medical Lab Technology, Chandigarh University, Gharuan, Mohali, 140413, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpal Singh","family":"Buttar","sequence":"additional","affiliation":[{"name":"Department of\nPathology &amp; Laboratory Medicine, University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajad Ahmad","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department\nof Biochemistry, International Medical School, University of International Business (UIB), Almaty, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuftieva","family":"Ainur","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, International Medical School, University of International Business (UIB), Almaty,\nKazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tannu","family":"Priya","sequence":"additional","affiliation":[{"name":"Department of Medical Lab Technology, Chandigarh University, Gharuan, Mohali, 140413, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharambir","family":"Kashyap","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER),\nChandigarh 160012, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardeep Singh","family":"Tuli","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University),\nMullana-Ambala 133 207, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"Bastuji-Garin S.","year":"1993","unstructured":"Bastuji-Garin S.; Rzany B.; Stern R.S.; Shear N.H.; Naldi L.; Roujeau J.C.; Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993,129(1),92-96","journal-title":"Arch Dermatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.humimm.2014.09.022","volume":"75","author":"Aggarwal R.","year":"2014","unstructured":"Aggarwal R.; Sharma M.; Modi M.; Garg V.; Salaria M.; HLA-B 1502 is associated with carbamazepine induced Stevens Johnson syndrome in North Indian population. Hum Immunol 2014,75(11),1120-1122","journal-title":"Hum Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","volume":"68","author":"Lyell A.","year":"1956","unstructured":"Lyell A.; Toxic epidermal necrolysis: An eruption resembling scalding of the skin. Br J Dermatol 1956,68(11),355-361","journal-title":"Br J Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/9781118357606.ch68","author":"Roujeau J.C.","year":"2014","unstructured":"Roujeau J.C.; Ghislain P.D.; Valleyrie-Allanore L.;  Evidence-Based Dermatology 2014,578-585","journal-title":"Evidence-Based Dermatology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","volume":"28","author":"La Grenade L","year":"2005","unstructured":"La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A; Bonnel R.; Karwoski C.; Governale L.; Brinker A.; Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005,28(10),917-24","journal-title":"Drug Saf"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/archderm.1995.01690220120030","volume":"131","author":"Chan H.L.","year":"1995","unstructured":"Chan H.L.; Toxic epidermal necrolysis in Singapore, 1989 through 1993: Incidence and antecedent drug exposure. Arch Dermatol 1995,131(10),1212-1213","journal-title":"Arch Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/CCID.S356450","volume":"15","author":"Primisawitri P.P.","year":"2022","unstructured":"Primisawitri P.P.; Mawardi P.; The correlation of neutrophil\u2013lymphocyte ratio and eosinophil count with SCORTEN in SJS\/TEN. Clin Cosmet Investig Dermatol 2022,15,547-556","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"Lonjou C.","year":"2008","unstructured":"Lonjou C.; Borot N.; Sekula P.; A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008,18(2),99-107","journal-title":"Pharmacogenet Genomics"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"Hung S.I.","year":"2005","unstructured":"Hung S.I.; Chung W.H.; Liou L.B.; HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005,102(11),4134-4139","journal-title":"Proc Natl Acad Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","volume":"81","author":"Weinkle A.","year":"2019","unstructured":"Weinkle A.; Pettit C.; Jani A.; Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation\u2014A retrospective chart review. J Am Acad Dermatol 2019,81(3),749-757","journal-title":"J Am Acad Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/medicina57090895","volume":"57","author":"Frantz R.","year":"2021","unstructured":"Frantz R.; Huang S.; Are A.; Motaparthi K.; Stevens\u2013johnson syndrome and toxic epidermal necrolysis: A review of diagnosis and management. Medicina 2021,57(9),895","journal-title":"Medicina"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","volume":"62","author":"Yip L.W.","year":"2007","unstructured":"Yip L.W.; Thong B.Y.; Lim J.; Ocular manifestations and complications of Stevens-johnson syndrome and toxic epidermal necrolysis: An Asian series. Allergy 2007,62(5),527-531","journal-title":"Allergy"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/B978-0-12-814647-7.00009-9","author":"Brody T.","year":"2018","unstructured":"Brody T.;  FDA\u2019s Drug Rev Process Packag Label 2018,387-440","journal-title":"FDA\u2019s Drug Rev Process Packag Label"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4103\/jfmpc.jfmpc_889_19","volume":"9","author":"Maity S.","year":"2020","unstructured":"Maity S.; Banerjee I.; Sinha R.; Jha H.; Ghosh P.; Mustafi S.; Nikolsky\u2019s sign: A pathognomic boon. J Family Med Prim Care 2020,9(2),526-530","journal-title":"J Family Med Prim Care"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000070938","volume":"207","author":"Magina S.","year":"2003","unstructured":"Magina S.; Lisboa C.; Leal V.; Palmares J.; Mesquita-Guimar\u00e3es J.; Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003,207(1),33-36","journal-title":"Dermatology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1542\/peds.109.1.74","volume":"109","author":"Sheridan R.L.","year":"2002","unstructured":"Sheridan R.L.; Schulz J.T.; Ryan C.M.; Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002,109(1),74-78","journal-title":"Pediatrics"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","volume":"27","author":"Oplatek A.","year":"2006","unstructured":"Oplatek A.; Brown K.; Sen S.; Halerz M.; Supple K.; Gamelli R.L.; Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006,27(1),26-33","journal-title":"J Burn Care Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3889\/oamjms.2018.148","volume":"6","author":"Fakoya A.O.J.","year":"2018","unstructured":"Fakoya A.O.J.; Omenyi P.; Anthony P.; Stevens-johnson syndrome and toxic epidermal necrolysis; extensive review of reports of drug-induced etiologies, and possible therapeutic modalities. Open Access Maced J Med Sci 2018,6(4),730-738","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/S0140-6736(85)90771-8","volume":"326","author":"Roujeau J.C.","year":"1985","unstructured":"Roujeau J.C.; Guillaume J.C.; Revuz J.; Touraine R.; Reporting adverse drug reactions. Lancet 1985,326(8466),1244","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","volume":"48","author":"Man C.B.L.","year":"2007","unstructured":"Man C.B.L.; Kwan P.; Baum L.; Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007,48(5),1015-1018","journal-title":"Epilepsia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"Chung W.H.","year":"2004","unstructured":"Chung W.H.; Hung S.I.; Hong H.S.; A marker for Stevens\u2013Johnson syndrome. Nature 2004,428(6982),486","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","volume":"16","author":"Hung S.I.","year":"2006","unstructured":"Hung S.I.; Chung W.H.; Jee S.H.; Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006,16(4),297-306","journal-title":"Pharmacogenet Genomics"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","volume":"49","author":"Locharernkul C.","year":"2008","unstructured":"Locharernkul C.; Loplumlert J.; Limotai C.; Carbamazepine and phenytoin induced Stevens-johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008,49(12),2087-2091","journal-title":"Epilepsia"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","volume":"6","author":"Lonjou C.","year":"2006","unstructured":"Lonjou C.; Thomas L.; Borot N.; A marker for Stevens-johnson syndrome\u2026: ethnicity matters. Pharmacogenomics J 2006,6(4),265-268","journal-title":"Pharmacogenomics J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1346-8138.2008.00548.x","volume":"35","author":"Kashiwagi M.","year":"2008","unstructured":"Kashiwagi M.; Aihara M.; Takahashi Y.; Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 2008,35(10),683-685","journal-title":"J Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eplepsyres.2010.10.006","volume":"92","author":"An D.M.","year":"2010","unstructured":"An D.M.; Wu X.T.; Hu F.Y.; Yan B.; Stefan H.; Zhou D.; Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res 2010,92(2-3),226-230","journal-title":"Epilepsy Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/ijd.12570","volume":"54","author":"Zeng T.","year":"2015","unstructured":"Zeng T.; Long Y.S.; Min F.L.; Liao W.P.; Shi Y.W.; Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: A meta-analysis. Int J Dermatol 2015,54(4),488-493","journal-title":"Int J Dermatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","volume":"9","author":"Kaniwa N.","year":"2008","unstructured":"Kaniwa N.; Saito Y.; Aihara M.; HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens\u2013johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008,9(11),1617-1622","journal-title":"Pharmacogenomics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","volume":"51","author":"Tassaneeyakul W.","year":"2010","unstructured":"Tassaneeyakul W.; Tiamkao S.; Jantararoungtong T.; Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010,51(5),926-930","journal-title":"Epilepsia"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","volume":"5","author":"Harr T.","year":"2010","unstructured":"Harr T.; French L.E.; Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010,5(1),39","journal-title":"Orphanet J Rare Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"Ko T.M.","year":"2011","unstructured":"Ko T.M.; Chung W.H.; Wei C.Y.; Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011,128(6),1266-1276.e11","journal-title":"J Allergy Clin Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","volume":"123","author":"Nassif A.","year":"2004","unstructured":"Nassif A.; Moslehi H.; Le Gouvello S.; Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004,123(5),850-855","journal-title":"J Invest Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","volume":"129","author":"Wei C.Y.","year":"2012","unstructured":"Wei C.Y.; Chung W.H.; Huang H.W.; Chen Y.T.; Hung S.I.; Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012,129(6),1562-1569.e5","journal-title":"J Allergy Clin Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"Viard I.","year":"1998","unstructured":"Viard I.; Wehrli P.; Bullani R.; Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998,282(5388),490-493","journal-title":"Science"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"Chung W.H.","year":"2008","unstructured":"Chung W.H.; Hung S.I.; Yang J.Y.; Granulysin is a key mediator for disseminated keratinocyte death in Stevens-johnson syndrome and toxic epidermal necrolysis. Nat Med 2008,14(12),1343-1350","journal-title":"Nat Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"16183","DOI":"10.1074\/jbc.M212188200","volume":"278","author":"Viard-Leveugle I.","year":"2003","unstructured":"Viard-Leveugle I.; Bullani R.R.; Meda P.; Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003,278(18),16183-16188","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","volume":"122","author":"Murata J.","year":"2008","unstructured":"Murata J.; Abe R.; Shimizu H.; Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008,122(5),992-1000","journal-title":"J Allergy Clin Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1084\/jem.187.8.1205","volume":"187","author":"Schneider P.","year":"1998","unstructured":"Schneider P.; Holler N.; Bodmer J.L.; Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998,187(8),1205-1213","journal-title":"J Exp Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"Lerch M.","year":"2018","unstructured":"Lerch M.; Mainetti C.; Terziroli Beretta-Piccoli B.; Harr T.; Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 2018,54(1),147-176","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/bjd.15360","volume":"177","author":"Lee H.Y.","year":"2017","unstructured":"Lee H.Y.; Walsh S.A.; Creamer D.; Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up. Br J Dermatol 2017,177(4),924-935","journal-title":"Br J Dermatol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"Mockenhaupt M.","year":"2008","unstructured":"Mockenhaupt M.; Viboud C.; Dunant A.; Stevens-johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008,128(1),35-44","journal-title":"J Invest Dermatol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","volume":"353","author":"Rzany B.","year":"1999","unstructured":"Rzany B.; Correia O.; Kelly J.P.; Naldi L.; Auquier A.; Stern R.; Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: A case-control study. Lancet 1999,353(9171),2190-2194","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","volume":"64","author":"Mockenhaupt M.","year":"2005","unstructured":"Mockenhaupt M.; Messenheimer J.; Tennis P.; Schlingmann J.; Risk of Stevens-johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005,64(7),1134-1138","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"874445","DOI":"10.3389\/fmed.2022.874445","volume":"9","author":"DenAdel M.A.","year":"2022","unstructured":"DenAdel M.A.; Hendrickson S.E.; Fuchs E.; Stevens-johnson syndrome: Past, present, and future directions gynecologic manifestations and management in SJS\/TEN. Front Med 2022,9,874445","journal-title":"Front Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/CCID.S378106","volume":"15","author":"Ye Z.","year":"2022","unstructured":"Ye Z.; Li C.; Zhang H.; Zhang C.; Lu X.; Effectiveness and safety of early short-course, moderate- to high-dose glucocorticoids for the treatment of Stevens\u2013johnson syndrome\/toxic epidermal necrolysis: A retrospective study. Clin Cosmet Investig Dermatol 2022,15,1979-1990","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00431-022-04407-w","volume":"181","author":"Cendejas-Hernandez J.","year":"2022","unstructured":"Cendejas-Hernandez J.; Sarafian J.T.; Lawton V.G.; Paracetamol (acetaminophen) use in infants and children was never shown to be safe for neurodevelopment: A systematic review with citation tracking. Eur J Pediatr 2022,181(5),1835-1857","journal-title":"Eur J Pediatr"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjd.17841","volume":"181","author":"McPherson T.","year":"2019","unstructured":"McPherson T.; Exton L.S.; Biswas S.; British Association of Dermatologists\u2019 guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol 2019,181(1),37-54","journal-title":"Br J Dermatol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","volume":"114","author":"Tapia B.","year":"2004","unstructured":"Tapia B.; Padial A.; S\u00e1nchez-Sabat\u00e9 E.; Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004,114(2),335-340","journal-title":"J Allergy Clin Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","volume":"8","author":"Wang F.","year":"2018","unstructured":"Wang F.; Ye Y.; Luo Z.Y.; Gao Q.; Luo D.Q.; Zhang X.; Diverse expression of TNF-\u03b1 and CCL27 in serum and blister of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. Clin Transl Allergy 2018,8(1),12","journal-title":"Clin Transl Allergy"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.12968\/jowc.2021.30.12.1012","volume":"30","author":"Houschyar K.S.","year":"2021","unstructured":"Houschyar K.S.; Tapking C.; Borrelli M.R.; Stevens\u2013johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. J Wound Care 2021,30(12),1012-1019","journal-title":"J Wound Care"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/ddg.14118","volume":"18","author":"Gr\u00fcnwald P.","year":"2020","unstructured":"Gr\u00fcnwald P.; Mockenhaupt M.; Panzer R.; Emmert S.; Erythema multiforme, Stevens-johnson syndrome\/toxic epidermal necrolysis \u2013 diagnosis and treatment. J Dtsch Dermatol Ges 2020,18(6),547-553","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","volume":"38","author":"Noe M.H.","year":"2020","unstructured":"Noe M.H.; Micheletti R.G.; Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Clin Dermatol 2020,38(6),607-612","journal-title":"Clin Dermatol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.23750\/ABM.V90I3-S.8165","volume":"90","author":"Liotti L.","year":"2019","unstructured":"Liotti L.; Caimmi S.; Bottau P.; Clinical features, outcomes and treatment in children with drug induced Stevens-johnson syndrome and toxic epidermal necrolysis. Acta Biomed 2019,90(3-S),52-60","journal-title":"Acta Biomed"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","volume":"32","author":"Sekula P.","year":"2011","unstructured":"Sekula P.; Liss Y.; Davidovici B.; Evaluation of SCORTEN on a cohort of patients with Stevens-johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011,32(2),237-245","journal-title":"J Burn Care Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jdv.16685","volume":"35","author":"Torres-Navarro I.","year":"2021","unstructured":"Torres-Navarro I.; Briz-Red\u00f3n \u00c1.; Botella-Estrada R.; Systemic therapies for Stevens\u2013johnson syndrome and toxic epidermal necrolysis: A SCORTEN-based systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2021,35(1),159-171","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/archderm.136.3.323","volume":"136","author":"Garcia-Doval I.","year":"2000","unstructured":"Garcia-Doval I.; LeCleach L.; Bocquet H.; Otero X.L.; Roujeau J.C.; Toxic epidermal necrolysis and Stevens-johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000,136(3),323-327","journal-title":"Arch Dermatol"},{"key":"ref=57","doi-asserted-by":"publisher","author":"Ramien M","unstructured":"Ramien M; Goldman JL; Pediatric SJS-TEN; Pediatric SJS-TEN: Where are we now? F1000Res 2020; 9: F1000 Faculty Rev-982.","DOI":"10.12688\/f1000research.20419.1"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","volume":"157","author":"Kridin K.","year":"2021","unstructured":"Kridin K.; Br\u00fcggen M.C.; Chua S.L.; Assessment of treatment approaches and outcomes in stevens-johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol 2021,157(10),1182-1190","journal-title":"JAMA Dermatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.mcna.2021.04.001","volume":"105","author":"Owen C.E.","year":"2021","unstructured":"Owen C.E.; Jones J.M.; Recognition and management of severe cutaneous adverse drug reactions (Including Drug Reaction with eosinophilia and systemic symptoms, stevens-johnson syndrome, and toxic epidermal Necrolysis). Med Clin North Am 2021,105(4),577-597","journal-title":"Med Clin North Am"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","volume":"23","author":"Palmieri T.L.","year":"2002","unstructured":"Palmieri T.L.; Greenhalgh D.G.; Saffle J.R.; A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002,23(2),87-96","journal-title":"J Burn Care Rehabil"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/jbcr\/iraa082","volume":"41","author":"Nygaard R.M.","year":"2020","unstructured":"Nygaard R.M.; Endorf F.W.; Differences in treatment of stevens-johnson syndrome and toxic epidermal necrolysis at burn centers and nonburn centers. J Burn Care Res 2020,41(5),945-950","journal-title":"J Burn Care Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/TME.0000000000000225","volume":"41","author":"Woolum J.A.","year":"2019","unstructured":"Woolum J.A.; Bailey A.M.; Baum R.A.; Metts E.L.; A review of the management of stevens\u2013johnson syndrome and toxic epidermal necrolysis. Adv Emerg Nurs J 2019,41(1),56-64","journal-title":"Adv Emerg Nurs J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","volume":"59","author":"Maloney N.J.","year":"2020","unstructured":"Maloney N.J.; Ravi V.; Cheng K.; Bach D.Q.; Worswick S.; Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review. Int J Dermatol 2020,59(6),e183-e188","journal-title":"Int J Dermatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2340\/00015555-0214","volume":"87","author":"Kardaun S.H.","year":"2007","unstructured":"Kardaun S.H.; Jonkman M.F.; Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis. Acta Derm Venereol 2007,87(2),144-148","journal-title":"Acta Derm Venereol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","volume":"58","author":"Schneck J.","year":"2008","unstructured":"Schneck J.; Fagot J.P.; Sekula P.; Sassolas B.; Roujeau J.C.; Mockenhaupt M.; Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008,58(1),33-40","journal-title":"J Am Acad Dermatol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","volume":"352","author":"Wolkenstein P.","year":"1998","unstructured":"Wolkenstein P.; Latarjet J.; Roujeau J.C.; Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998,352(9140),1586-1589","journal-title":"Lancet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"750173","DOI":"10.3389\/fphar.2021.750173","volume":"12","author":"Yang L.","year":"2022","unstructured":"Yang L.; Shou Y.H.; Li F.; Zhu X.H.; Yang Y.S.; Xu J.H.; Intravenous immunoglobulin combined with corticosteroids for the treatment of Stevens\u2013Johnson Syndrome\/toxic epidermal necrolysis: A propensity-matched retrospective study in China. Front Pharmacol 2022,12,750173","journal-title":"Front Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","volume":"153","author":"Zimmermann S.","year":"2017","unstructured":"Zimmermann S.; Sekula P.; Venhoff M.; Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol 2017,153(6),514-522","journal-title":"JAMA Dermatol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/17469872.2.3.299","volume":"2","author":"Trent J.T.","year":"2007","unstructured":"Trent J.T.; Ma F.; Kerdel F.; Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol 2007,2(3),299-303","journal-title":"Expert Rev Dermatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","volume":"34","author":"Schneider J.A.","year":"2017","unstructured":"Schneider J.A.; Cohen P.R.; Stevens-Johnson syndrome and toxic epidermal necrolysis: A concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther 2017,34(6),1235-1244","journal-title":"Adv Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/pde.13236","volume":"34","author":"St John J.","year":"2017","unstructured":"St John J.; Vladimir R.; Kristina J.L.; Successful use of cyclosporin A for stevens\u2013johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 2017,34,540-546","journal-title":"Pediatr Dermatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/0378-6323.41379","volume":"74","author":"Srinivas C.R.","year":"2008","unstructured":"Srinivas C.R.; Rai R.; Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2008,74(3),263-265","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/00015550310005906","volume":"84","author":"Hashim N.","year":"2003","unstructured":"Hashim N.; Bandara D.; Tan E.; Ilchyshyn A.; Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. Acta Derm Venereol 2003,84(1),90-91","journal-title":"Acta Derm Venereol"},{"key":"ref=74","first-page":"31","volume":"32","author":"Robak E.","year":"2001","unstructured":"Robak E.; Robak T.; G\u00f3ra-Tybor J.; Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med 2001,32(1-2),31-39","journal-title":"J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","volume":"163","author":"Valeyrie-Allanore L.","year":"2010","unstructured":"Valeyrie-Allanore L.; Wolkenstein P.; Brochard L.; Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010,163(4),847-853","journal-title":"Br J Dermatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","volume":"116","author":"Hunger R.E.","year":"2005","unstructured":"Hunger R.E.; Hunziker T.; Buettiker U.; Braathen L.R.; Yawalkar N.; Rapid resolution of toxic epidermal necrolysis with anti-TNF-\u03b1 treatment. J Allergy Clin Immunol 2005,116(4),923-924","journal-title":"J Allergy Clin Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","volume":"21","author":"Meiss F.","year":"2007","unstructured":"Meiss F.; Helmbold P.; Meykadeh N.; Gaber G.; Marsch W.Ch.; Fischer M.; Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007,21(5),717-719","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","volume":"121","author":"Kamanabroo D.","year":"1985","unstructured":"Kamanabroo D.; Schmitz-Landgraf W.; Czarnetzki B.M.; Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985,121(12),1548-1549","journal-title":"Arch Dermatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","volume":"2","author":"Yamada H.","year":"1998","unstructured":"Yamada H.; Takamori K.; Yaguchi H.; Ogawa H.; A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher 1998,2(2),153-156","journal-title":"Ther Apher"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s001340051063","volume":"25","author":"Furubacke A.","year":"1999","unstructured":"Furubacke A.; Berlin G.; Anderson C.; Sj\u00f6berg F.; Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999,25(11),1307-1310","journal-title":"Intensive Care Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","volume":"25","author":"Heng M.C.Y.","year":"1991","unstructured":"Heng M.C.Y.; Allen S.G.; Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991,25(5),778-786","journal-title":"J Am Acad Dermatol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","volume":"48","author":"Ar\u00e9valo J.M.","year":"2000","unstructured":"Ar\u00e9valo J.M.; Lorente J.A.; Gonz\u00e1lez-Herrada C.; Jim\u00e9nez-Reyes J.; Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000,48(3),473-478","journal-title":"J Trauma"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","volume":"89","author":"Frangogiannis N.G.","year":"1996","unstructured":"Frangogiannis N.G.; Boridy I.; Mazhar M.; Mathews R.; Gangopadhyay S.; Cate T.; Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996,89(10),1001-1003","journal-title":"South Med J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"649369","DOI":"10.3389\/fmed.2021.649369","volume":"8","author":"Wakamatsu T.H.","year":"2021","unstructured":"Wakamatsu T.H.; dos Santos M.S.; Barreiro T.P.; Clinical aspects of stevens-johnson syndrome and toxic epidermal necrolysis with severe ocular complications in Brazil. Front Med 2021,8,649369","journal-title":"Front Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"640360","DOI":"10.3389\/fmed.2021.640360","volume":"8","author":"Kim M.K.","year":"2021","unstructured":"Kim M.K.; Yoon K.C.; Yoon S.H.; Seo K.Y.; Clinical aspects of stevens-johnson syndrome and toxic epidermal necrolysis with severe ocular complications in South Korea. Front Med 2021,8,640360","journal-title":"Front Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/archotol.124.12.1375","volume":"124","author":"Barrera J.E.","year":"1998","unstructured":"Barrera J.E.; Meyers A.D.; Hartford E.C.; Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis. Arch Otolaryngol Head Neck Surg 1998,124(12),1375-1376","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref=87","first-page":"53","volume":"3","author":"Romano A.","year":"1993","unstructured":"Romano A.; Di Fonso M.; Pocobelli D.; Giannarini L.; Venuti A.; Garcovich A.; Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to \u03b2-lactam antibiotics. J Investig Allergol Clin Immunol 1993,3(1),53-55","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4321\/S0212-71992008000100015","volume":"25","author":"Asensio-S\u00e1nchez V.M.","year":"2008","unstructured":"Asensio-S\u00e1nchez V.M.; Toxic epidermal necrosis due to dorzolamide eye drops. An Med Interna 2008,25(1),47-48","journal-title":"An Med Interna"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","volume":"35","author":"Wolkenstein P.","year":"1996","unstructured":"Wolkenstein P.; Chosidow O.; Fl\u00e9chet M.L.; Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermat 1996,35(4),234-236","journal-title":"Contact Dermat"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","volume":"59","author":"Pichler W.J.","year":"2004","unstructured":"Pichler W.J.; Tilch J.; The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004,59(8),809-820","journal-title":"Allergy"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","volume":"62","author":"Kano Y.","year":"2007","unstructured":"Kano Y.; Hirahara K.; Mitsuyama Y.; Takahashi R.; Shiohara T.; Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007,62(12),1439-1444","journal-title":"Allergy"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1398-9995.2007.01516.x","volume":"63","author":"Beeler A.","year":"2008","unstructured":"Beeler A.; Zaccaria L.; Kawabata T.; Gerber B.O.; Pichler W.J.; CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 2008,63(2),181-188","journal-title":"Allergy"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ijd.14409","volume":"58","author":"Zhang A.J.","year":"2019","unstructured":"Zhang A.J.; Nygaard R.M.; Endorf F.W.; Hylwa S.A.; Stevens-johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol 2019,58(9),1069-1077","journal-title":"Int J Dermatol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ijd.14544","volume":"59","author":"Medeiros M.P.","year":"2020","unstructured":"Medeiros M.P.; Carvalho C.H.C.; Santi C.G.; Avancini J.; Stevens-johnson syndrome and toxic epidermal necrolysis \u2013 retrospective review of cases in a high complexity hospital in Brazil. Int J Dermatol 2020,59(2),191-196","journal-title":"Int J Dermatol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","volume":"84","author":"Tsai T.Y.","year":"2021","unstructured":"Tsai T.Y.; Huang I.H.; Chao Y.C.; Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol 2021,84(2),390-397","journal-title":"J Am Acad Dermatol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000148255","volume":"217","author":"Yun S.J.","year":"2008","unstructured":"Yun S.J.; Choi M.S.; Piao M.S.; Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology 2008,217(3),254-259","journal-title":"Dermatology"}],"container-title":["Recent Advances in Inflammation &amp; Allergy Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772270817666230821102441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220050\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772270817666230821102441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T12:17:20Z","timestamp":1701087440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220050\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2772270817666230821102441","relation":{},"ISSN":["2772-2708"],"issn-type":[{"value":"2772-2708","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}